Alan L. Ho

University of Miami — United States

Medicine · Health Sciences

60h-index22.9kcitations533works2.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Salivary Gland Tumors Diagnosis and Treatment(148), Thyroid Cancer Diagnosis and Treatment(93), Lung Cancer Treatments and Mutations(56), Cell Adhesion Molecules Research(45), Head and Neck Cancer Studies(42)

Publications532 total

Post-Operative Endocrinological Outcomes for Patients Undergoing Surgery for Tuberculum Sellae Meningiomas: Case Series and Systematic Review
Journal of Neurological Surgery Part B Skull Base·2026
Differential Disruption of Functional Networks in Patients with Vestibular Schwannoma
Journal of Neurological Surgery Part B Skull Base·2026
Intensity-modulated proton therapy vs intensity-modulated radiotherapy in nasopharyngeal carcinoma: a case–control study
The Lancet Regional Health - Americas·2025Open Access
Head and Neck Cancer
JAMA·2025· 2 cited
Osteoradionecrosis After Intensity-Modulated Radiation Therapy or Proton Therapy in Oropharyngeal Carcinoma
JAMA Otolaryngology–Head & Neck Surgery·2025· 1 citedOpen Access
Table S3 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
2025Open Access
Table S6 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
2025Open Access
Figure S2 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
2025Open Access
Figure S1 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
2025Open Access
Table S5 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
2025Open Access
Table S2 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
2025Open Access
Table S1 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
2025Open Access
Figure S4 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
2025Open Access
Table S4 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
2025Open Access
Figure S3 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
2025Open Access
Supplementary Figure from Mutated HRAS Activates YAP1–AXL Signaling to Drive Metastasis of Head and Neck Cancer
2025Open Access
Supplementary Data from Mutated HRAS Activates YAP1–AXL Signaling to Drive Metastasis of Head and Neck Cancer
2025Open Access
Supplementary figures S1-S5 from Tipifarnib Potentiates the Antitumor Effects of PI3Kα Inhibition in <i>PIK3CA</i>- and <i>HRAS</i>-Dysregulated HNSCC via Convergent Inhibition of mTOR Activity
2025Open Access
Proton Therapy for Paranasal Sinus Cancer: Clinical Outcomes and Patterns of Failure
Head & Neck·2025
Pathologic Response to Neoadjuvant Cetuximab, Platinum, and Taxane in Locally Advanced HNSCC
Otolaryngology·2025Open Access
page 1 of 27Next →

Frequent Co-authors

David G. Pfister(13), Eric J. Sherman(13), Luc G.T. Morris(12), Ronald Ghossein(12), Nora Katabi(12), Timothy A. Chan(9), Ian Ganly(9), Shrujal S. Baxi(8), Richard J. Wong(8), Nadeem Riaz(8), Nancy Y. Lee(7), David B. Solit(7), James A. Fagin(7), Lara Dunn(7), Snjezana Doğan(7), Michael F. Berger(6), Jorge S. Reis‐Filho(6), Martin G. Dalin(6), Ashok R. Shaha(6), Ahmet Zehir(5)